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Abstract
Background & Aims: HCV Council 2014, like its predecessor HCV Council 2011, assembled leading clinicians and research-
ers in the field of hepatitis C to critically evaluate current data regarding best practices for managing patients with chronic
hepatitis C virus (HCV). Methods: Clinical practice statements were developed that reflect the areas of potential controversy
with high clinical impact. Faculty members were responsible for reviewing the literature to support or reject these state-
ments. After a review and comprehensive discussion of the data, the HCV Council faculty voted on the nature of the evi-
dence and the level of support for each statement. Results: The results of the detailed analysis with expert opinion are
summarized in this article. Conclusion: Numerous questions regarding optimal management of certain populations and
clinical scenarios remain unanswered. The discussion in the article provides a summary of evidenced-based expert opinion
that may help guide clinicians as additional information is developed.
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The therapeutic landscape for the treatment of chronic hep-
atitis C virus (HCV) infection has been rapidly evolving
since the approval of the first direct-acting antiviral agents
(DAAs), telaprevir and boceprevir, in 2011. In 2013, sofos-
buvir (SOF) became the first nucleoside NS5B polymerase
inhibitor to be approved and offered a potent DAA with a
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high genetic-barrier that led the transformation of HCV
treatment to all-oral regimens. Over the last 2 years, the US
Food and Drug Administration (FDA) approved four all-
oral regimens: (i) SOF plus ribavirin (RBV); (ii) SOF plus
simeprevir (SMV), an NS3 protease inhibitor (PI); (iii) the
fixed-dose combination of SOF with the NS5A inhibitor
ledipasvir (LDV/SOF) (1); and (iv) a 3 DAA (3D) ± RBV
regimen [paritaprevir (NS3/4A PI) boosted with ritonavir,
ombitasvir (NS5A inhibitor) and dasabuvir (non-nucleoside
NS5B polymerase inhibitor)]. The Phase 3 clinical trials pro-
vided guidance for the FDA labelling and informed clini-
cians about optimizing therapy with these drugs. However,
not all patient scenarios can be anticipated, and often a
more nuanced interpretation of Phase 3 trial results, cou-
pled with rapidly evolving data from ongoing Phase 2 clini-
cal trials, will also provide important information to guide
practice. In 2013, the American Association for the Study of
Liver Diseases (AASLD) and Infectious Diseases Society of
America (IDSA)/International Antiviral Society USA (IAS–
USA) formed a task force to provide ongoing treatment rec-
ommendations incorporating the most up-to-date clinical
data and to serve as an additional resource for clinicians
who manage patients with HCV (2).
Complementing this effort, the HCV Council 2014,
like its predecessor HCV Council 2011 (3), assembled
leading clinicians and researchers in the field of hepatitis
C in July 2014, to critically evaluate current data regard-
ing best practices for managing patients with chronic
HCV. The methodology of the HCV Council has been
described previously (3). Clinical practice statements
(Table 1) were developed that reflect areas of potential
controversy with high clinical impact. Faculty members
were responsible for reviewing the literature to support
or reject these statements. After a review and comprehen-
sive discussion of the data, the HCV Council faculty
voted on the nature of the evidence and the level of sup-
port for each statement (Table 2). Voting results were
based on data available in July 2014. Additional data
available from July 2014 to August 2015 have been added
to supplement the findings. The results of the detailed
analysis with expert opinion are summarized below.
Statement 1: patients with cirrhosis have lower
rates of sustained virological response compared
to non-cirrhotic patients and, thus, treatment
efficacy remains suboptimal for this population
Rationale and definition of statement
Patients with advanced fibrosis and cirrhosis are most
in need of HCV therapy, as successful therapy has
been shown to decrease liver-related mortality (4).
Interferon (IFN)-based antiviral treatment in these
patients had been challenging because of patient toler-
ance, the risk of serious adverse events, and hypo-
responsiveness to therapy. Bridging fibrosis and cir-
rhosis have traditionally been negative predictors of
HCV treatment outcome.
Summary of evidence
The disparity in sustained virological response (SVR)
between cirrhotic and non-cirrhotic patients was evi-
dent during treatment with peginterferon (PEG-IFN)
and RBV and was not mitigated by the addition of first
generation PIs (5, 6). The advent of all-oral DAA regi-
mens considerably altered the treatment landscape by
achieving superior tolerability as well as increased SVR
rates despite truncated treatment durations (Table 3).
The combination of LDV/SOF with or without RBV
given for 12 or 24 weeks, has been evaluated in subsets
of genotype 1 patients with cirrhosis in both treatment-
na€ıve and treatment-experienced patients (7, 8). The
SVR in treatment-na€ıve patients ranged from 94 to
100% (7). In cirrhotic patients who had failed therapy,
including a PI, this regimen achieved an SVR of 82 to
100% with higher SVR rates noted with the 24-week
regimen, regardless of the use of RBV (8). Further stud-
ies that were enriched with cirrhotic patients who had
failed prior PIs show that 12 weeks of LDV/SOF with
RBV has equivalent efficacy to 24 weeks of LDV/SOF
(9, 10).
In a trial exclusively for patients with cirrhosis who
were treatment-na€ıve or prior PEG-IFN/RBV failures,
the 3D regimen [paritaprevir/r (ritonavir boosted PI),
ombitasvir (an NS5A inhibitor) and dasabuvir (a non-
nucleoside inhibitor)], with RBV for 12 or 24 weeks
achieved high SVR rates of 92–96% respectively. Prior
null responders and those with genotype 1a had a
slightly lower numerical response of 87 and 89%,
respectively, with a 12-week regimen, while the 24-week
regimen achieved an SVR of 95 and 94% respectively
(11). The presence of cirrhosis also lowers efficacy in
non-genotype 1 patients, as highlighted below.
Discussion
The panel agreed that all-oral therapy for patients with
HCV and cirrhosis has been a major advancement.
Although many of the traditional treatment obstacles
Key points
• HCV Council assembled leading clinicians and
researchers in the field of hepatitis C to critically eval-
uate current data regarding best practices for manag-
ing patients with chronic hepatitis C virus.
• Clinical practice statements were developed in the
field of hepatitis C that reflect areas of potential con-
troversy with high clinical impact.
• After a review and comprehensive discussion of the
data, the HCV Council faculty voted on the nature of the
evidence and the level of support for each statement.
• The discussion in the article provides a summary of
evidenced-based expert opinion that may help guide
clinicians as additional information is developed.
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have been overcome and patients with cirrhosis can
expect high SVR rates, challenges remain. Subsets of
patients with cirrhosis, particularly those with prior
treatment failure, will require a longer duration of ther-
apy or other modifications, such as the addition of
RBV, to maximize treatment response. Benefit in
patients with decompensated cirrhosis is under active
investigation.
Statement 2: patients with easier-to-treat
characteristics can be defined and treated for
shorter duration
Rationale and definition of statement
From the outset of HCV antiviral therapy, host and viral
factors predicted an ability to shorten therapy without a
compromise in efficacy. Low baseline viral levels, the
presence of IL28B CC, and rapid on-treatment virologi-
cal decay represented parameters that allowed for SVR
with shorter durations of IFN-based regimens (12–14).
Early-stage liver disease, likewise, reflected a cohort that
was ‘easier-to-treat’. Entering into the all-oral DAA era
where cost and compliance will drive therapy, there
have been attempts made to shorten treatment dura-
tions further.
Summary of evidence
In the ION-3 program, two 8-week regimens of LDV/
SOF were compared with one 12-week regimen among
non-cirrhotic genotype 1 patients, and the SVR rates
were similar in the shorter duration arms (15). These
results support the notion that ‘easier-to-treat’ non-
cirrhotic patients could shorten therapy.
Nevertheless, there were numerically more relapsers
in the 8-week arms, leading to concern that using a
shorter duration for all non-cirrhotic genotype 1
patients may come with unacceptable relapse rates and
without a defined salvage regimen (15). Post-hoc analy-
ses suggested that treatment na€ıve, non-cirrhotic
patients with HCV RNA levels <6 million IU did well
with 8 weeks of LDV/SOF and that relapse rates were
comparable to 12-week regimens, leading to the FDA
recommendation that 8 weeks of treatment can be con-
sidered in this subset. Additional post-hoc analysis also
found that gender and IL28B genotype were associated
with favourable response. There was a numeric but not
statistically significant difference in race, age and
subgenotype (16). The phase 2b study, AVIATOR, also
demonstrated a higher relapse rate in treatment-na€ıve
non-cirrhotic patients treated with 8 weeks of 3D (88%
SVR24 compared to 96% with 12 weeks) (17). In addi-
tion, in the 3D development program, to optimize prior
null responders to PEG-IFN/RBV who had cirrhosis
and genotype 1a, a longer, 24-week course offered
Table 1. HCV Council statements for evaluation
Workshop I: clinical management and treatment strategies: utilizing the new SOC in HCV
Patients with cirrhosis have lower rates of SVR compared to non-cirrhotic patients and, thus, treatment efficacy remains suboptimal for this
population
Patients with easier-to-treat characteristics can be defined and treated for shorter duration
Genotype 1a and 1b will be treated with different regimens
The preferred approach to treatment for all subgroups of patients with genotype 3 is sofosbuvir and ribavirin for 24 weeks
The preferred approach to treatment for all subgroups of patients with genotype 2 is sofosbuvir and ribavirin for 12 weeks. See the
supplemental section for review of this statement
Workshop II: a patient-oriented approach: addressing treatment challenges
Due to the high costs of medications, only patients with advanced fibrosis should be offered treatment with all-oral regimens for HCV
Given the high-efficacy and low-viral breakthrough rates, on-treatment viral load monitoring is no longer required
Patients with decompensated cirrhosis should be treated with an all-oral regimen for HCV to improve survival
Patients co-infected with HIV-HCV should no longer be considered a ‘special population’. See the supplemental section for review of this
statement
Treatment of hepatitis C should remain within the domain of hepatologists, gastroenterologists and ID physicians. See the supplemental
section for review of this statement
Table 2. Council voting schemes
Category Nature of evidence
I Evidence obtained from at least 1 well-designed,
randomized, controlled trial
II Evidence obtained from well-designed cohort or
case-controlled studies
III Evidence obtained from case series, case reports, or
flawed clinical trials
IV Opinions of respected authorities based on clinical
experience, descriptive studies, or reports of expert
committees
V Insufficient evidence to form an opinion
Level of support for each statement
1 Accept statement completely
2 Accept statement with some reservations
3 Accept statement with major reservations
4 Reject statement with reservations
5 Reject statement completely
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higher cure rates, as compared to the 12-week group
(11).
Discussion
Most Phase 3 trials of all-oral DAA therapy have focused
on lengthening therapy for more ‘difficult-to-treat’ pop-
ulations vs shortening therapy for those considered
‘easy-to-treat’. While evidence shows that certain
patients with mild disease can achieve high rates of SVR
with shorter duration of therapy, others, such as those
with cirrhosis, benefit from a longer duration of treat-
ment. Definitively excluding cirrhosis may be challeng-
ing in the real world. Misclassifying patients with
advanced fibrosis as ‘non-cirrhotic’ and mandating only
8 weeks of therapy could lead to higher than expected
relapse rates. Thus, although the majority of the Council
members agreed that the statement was supported by a
well-designed randomized controlled trial, considerable
controversy existed regarding whether such a blanket
statement could translate into clinical practice in 2015.
Statement 3: genotype 1a and 1b will be treated
with different regimens
Rationale and definition of statement
Higher rates of SVR with HCV genotype 1b compared
to genotype 1a were first recognized with PEG-IFN/RBV
(18). This trend was attenuated with the first DAAs,
telaprevir and boceprevir (19, 20). However, the Phase 3
registration trial of simeprevir-based triple therapy
(SMV/PEG-IFN/RBV) demonstrated substantially
higher rates of SVR in genotype 1b compared to
genotype 1a as a result of a pre-existing resistance muta-
tion Q80K, which occurs almost exclusively in HCV
genotype 1a (21). The impact of subtype was less appar-
ent with SOF-based triple therapy. Pooled data from the
Phase 3 NEUTRINO (22) and Phase 2 ATOMIC trials
(23) suggested an SVR advantage in genotype 1a (92%)
over genotype 1b (82%), although the latter group also
had disproportionately higher frequency of negative
response characteristics.
Summary of evidence
The combination of drugs or duration of therapy may
vary depending on HCV subtype. The PEARL-III and -
IV studies nicely demonstrated that the addition of RBV
to the 12-week 3D regimen does not enhance the effi-
cacy in genotype 1b (SVR 99.5% with RBV and 99.0%
without) (24). However, SVR rates were significantly
lower in the genotype 1a subjects that did not receive
RBV (97% with compared to 90.2% without) (Fig. 1)
(24). TURQUOISE-II found that a 24-week regimen
was optimal for genotype 1a patients with cirrhosis with
prior null response: SVR rates of 88.6% with 12 weeks
of treatment compared to 94.2% when extended to
24 weeks (11). This improvement in efficacy was not
seen in any other subgroup including those genotype 1b
patients with cirrhosis and prior null response (SVR
rates of 98.5% with 12 weeks compared to 100% with
24 weeks) (11). Lastly, the need to tailor a regimen by
subtype will depend on the agents utilized. The Phase 3
ION-1, ION-2 and ION-3 studies showed no difference
in efficacy between genotype 1 subtypes with or without
RBV for durations of 12 or 24 weeks, even when
shortening therapy to 8 weeks in a non-cirrhotic
Table 3. Sustained virological response between cirrhotic and non-cirrhotic genotype 1 patients
Treatment-na€ıve Non-cirrhotics Cirrhotics
Ledipasvir and sofosbuvir 12 Weeks
99% (176/177)
12 Weeks
94% (32/34)
Paritaprevir/r-ombitasvir + dasabuvir + RBV 12 Weeks
96.2% (455/473)
12 Weeks
94.2% (81/86)
24 Weeks
94.6% (70/74)
Treatment experienced
Non-cirrhotics Cirrhotics
12 Weeks 24 Weeks 12 Weeks 24 Weeks
Ledipasvir and sofosbuvir 95% (83/87) 99% (85/86) 86% (19/22) 100% (22/22)
Paritaprevir/r-ombitasvir + dasabuvir + RBV 96.3% (286/297) – Relapse
96.6% (28/29)
100% (23/23)
Partial response
94.4% (17/18)
100% (13/13)
Null response
86.7% (65/75)
95.2% (59/62)
Treatment-na€ıve or prior null responders Non-cirrhotics (F0–3) Cirrhotics (F4)
Simeprevir + sofosbuvir 12 weeks
95% (20/21)
24 weeks
95% (20/21)
12 weeks
86% (6/7)
24 weeks
100% (10/10)
Ledipasvir and sofosbuvir (LDV/SOF) (1), Afdhal et al. (7), Afdhal et al. (8), Poordad et al. (11), Feld et al. (50), Zeuzem et al. (53).
Simeprevir Prescribing Information. Janssen Therapeutics, Division of Janssen Products, Revised: November 2014.
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treatment-na€ıve cohort (7, 8, 15). However, baseline
testing NS5A resistance-associated variants (RAVs) may
be necessary in a subset of genotype 1a patients being
considered for therapy with grazoprevir-elbasvir, as the
presence of a baseline RAV lowered efficacy in the 1a
subgenotype but did not appear to affect outcomes in
genotype 1b patients (25).
Discussion
Although relatively simple treatment algorithms will
apply for most populations, the agents and length of
therapy will be directed by HCV subtype and disease
severity. This is reflected in the recently released
AASLD-IDSA guidance document (2). As supported by
the data above, subtype did not impact treatment rec-
ommendations when using combination LDV/SOF;
however, the addition of RBV to 3D was advised in all
individuals with G1a and, as well as treatment extension
to 24 weeks for G1a patients with cirrhosis irrespective
of prior treatment response (2). Other modifications
such as baseline RAV testing also may be needed to
optimize therapy based on subgenotype.
Statement 4: the preferred approach to treatment
for all subgroups of patients with genotype 2 is
SOF and RBV for 12 weeks
Rationale and definition of statement
Although genotype 2 is traditionally seen as the most
treatment-responsive type of HCV to cure, efficacy is
not 100% for all populations and alternative regimens
may be considered in special circumstances. The
AASLD-IDSA guidance recommends daily SOF
(400 mg) and weight-based RBV [1000 mg (<75 kg) to
1200 mg (≥75 kg)] for 12 weeks for treatment-naive or
treatment-experienced patients with HCV genotype 2
infection, with the additional caveat that 16 weeks of
therapy may be more beneficial for patients with cir-
rhosis based on the results of the FUSION trial (2).
The guidelines further suggested that an alternative reg-
imen for PEG-IFN/RBV non-responder patients with
HCV genotype 2 infection who are eligible to receive
IFN is retreatment with daily SOF (400 mg) and
weight-based RBV [1000 mg (<75 kg) to 1200 mg
(≥75 kg)] plus weekly PEG-IFN for 12 weeks, based on
the results of a small Phase 2 trial called LONESTAR
(2, 26).
Summary of evidence
Studies have demonstrated that genotype 2 patients
have high SVR rates with SOF + RBV for 12 weeks but
that cirrhosis and prior treatment response still affect
efficacy (27). There are additional meta-analysis data to
indicate that one needs at least five of six negative pre-
dictors in genotype 2 to see a significant decrease in the
efficacy of a SOF/RBV regimen (prior treatment, gender,
weight, IL28B, cirrhosis and HCV RNA levels), so most
patients will likely qualify for the 12 weeks of
SOF + RBV treatment (28). Treatment with daclatasvir
(DCV) + SOF for 24 weeks showed a 92% SVR in
genotype 2 patients, although the regimen was not
tested in patients with cirrhosis and was given for 24
rather than 12 weeks (29). DCV + SOF did show high
efficacy in G2 HCV-HIV co-infected patients treated for
12 weeks, making this a viable alternative for individu-
als who cannot tolerate RBV (30). The recently pre-
sented BOSON study also demonstrated high SVR12
rates in genotype 2 treatment-experienced cirrhotics
with 16 weeks of SOF/RBV (87%), SOF/RBV for
24 weeks (100%) and PEG-IFN/RBV + SOF for
12 weeks (94%) (31).
Fig. 1. 3D (paritaprevir/r-ombitasvir + dasabuvir) ± ribavirin (RBV). Ferenci et al. (24).
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Discussion
The opinion of the panel was split regarding the state-
ment with fair-to-poor evidence of support vs rejecting
the statement, mostly based on concerns about the effi-
cacy in prior treatment-experienced patients with cir-
rhosis. All Council members agreed that there was
insufficient evidence to support the statement fully,
likely because of doubts about cirrhotic non-responder
efficacy and the limited data that supports other thera-
pies available to this population. Nevertheless, in the
current therapeutic landscape, a 12-week regimen with
SOF/RBV remains the most efficacious for the majority
of patients with genotype 2.
Statement 5: the preferred approach to treatment
for all subgroups of patients with genotype 3 is
SOF and RBV for 24 weeks
Rationale and definition of statement
Hepatitis C virus G3 is associated with an increased risk
of cirrhosis and liver cancer. As a result, it has been identi-
fied as a population prioritized for therapy. Unfortu-
nately, available treatment alternatives may not offer high
rates of viral eradication. Recommended IFN-free regi-
mens for patients with HCV genotype 3 infection include
SOF/RBV administered for 24 weeks and SOF/DCV (2).
Summary of evidence
The first reported Phase 3 trials (FISSION, POSITRON
and FUSION) predominantly evaluated 12-week treat-
ment durations and showed substantially lower SVR
rates in genotype 3 compared with genotype 2 patients
(22, 27). Treatment-experienced patients with genotype
3 and cirrhosis were at the greatest disadvantage. The
FUSION study, demonstrating a marked increment in
SVR rates in genotype 3 patients when treatment was
given for 16 weeks rather than 12 weeks (37 vs 63% in
non-cirrhotics and 19 vs 61% in cirrhotics) (27), sug-
gested that a longer duration for genotype 3 patients
would be more effective. This hypothesis was validated
by the VALENCE trial, which evaluated 24-weeks of
SOF/RBV in 250 genotype 3 patients, and showed SVR
rates in 92–93% of treatment-na€ıve patients and 87% of
treatment-experienced non-cirrhotic patients (32).
However, the SVR rate of 62% in treatment-experienced
patients with cirrhosis was similar to the 61% SVR rate
in a comparable population that received 16 weeks of
treatment in FUSION (27).
Several observations suggest that a 12-week course of
PEG-IFN/RBV and SOF may offer comparable or even
superior efficacy to that attained with 24 weeks of SOF/
RBV in some genotype 3 patients. Thirty-nine genotype
3 treatment-na€ıve non-cirrhotic patients were treated for
12 weeks with SOF/RBV combined with 4–12 weeks of
PEG-IFN, with 38 (97%) achieving SVR (33). Another
modest-sized study presented at the European Associa-
tion for the Study of the Liver (EASL) 2014 lent credence
to the potential role of a 12-week triple regimen by
showing that both non-cirrhotic and cirrhotic genotype
3 patients who had failed a 12- to 16-week course of
SOF and RBV had higher SVR rates with 12 weeks of
PEG-IFN, RBV and SOF than with 24 weeks of SOF and
RBV (34). More recently, the BOSON trial showed supe-
rior efficacy with 12 weeks of triple therapy (n = 168/
181 with SVR12 93%) compared to 24 weeks of SOF/
RBV (n = 153/182 with SVR 84%) (31). Importantly,
PEG/RBV/SOF demonstrated higher SVR 12 rates in all
arms, regardless of cirrhosis status or treatment history.
Furthermore, it is possible that combinations of DAAs
will improve SVR rates. The ALLY-3 study demonstrated
overall SVR rates of 90 and 86% among treatment-na€ıve
and treatment-experienced patients, respectively, who
were treated with a 12-week regimen of SOF and DCV
(35). However, the SVR rate fell to 63% among genotype
3 cirrhotic patients treated with this regimen. Two ‘real
world’ studies presented at EASL 2015 clearly indicate
that extension of this regimen, with or without RBV, to
24 weeks confers superior results in this population (36–
38). As predicted by the relative in vitro activities, real-
world data from Foster et al. (38) showed a significant
benefit of DCV over ledipasvir for genotype 3 patients
when each agent was combined with SOF.
Discussion
Studies have demonstrated a propensity for HCV geno-
type 3 infection to cause progressive fibrosis, cirrhosis and
hepatocellular carcinoma (HCC) more frequently than is
seen in other HCV genotypes (39). In the light of this,
some clinicians perceive that a course of therapy that
leaves no resistance in the event of virological failure, as is
the case with SOF/RBV, should be offered to all patients
with genotype 3. Other clinicians may elect to use PEG-
IFN/RBV and SOF in selected patients. However, as
reflected in the updated HCV guidance documents, regi-
mens incorporating a second DAA, such as a potent,
pangenotypic NS5A inhibitor, with SOF is the preferred
first-line treatment for genotype 3 (40). As of August 7,
2015, SOF in combination with RBV for 24 weeks is con-
sidered only an alternative regimen. DCV/SOF for 12–
24 weeks and PEG-RBV/SOF for 12 weeks are the recom-
mended treatment options for genotype 3 patients.
Statement 6: due to the high costs of medications,
only patients with advanced fibrosis should be
offered treatment with all-oral regimens for HCV
Rationale and definition of statement
This statement is based on the premise that patients with
advanced fibrosis have the most risk and thus the most to
gain with therapy, while those with mild disease can wait.
Based on wholesale acquisition cost to treat the entire US
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HCV population would cost in excess of $300 billion, thus
the desire to prioritize and restrict access to therapy (41).
Summary of evidence
Hepatitis C virus has a significant effect on morbidity
and mortality that is highest in patients with cirrhosis,
but also impacts patients that are non-cirrhotic. In the
USA, chronic HCV is the most common cause of liver
disease. HCV is responsible for at least 15 000 deaths
annually, with increasing mortality expected over the
next decades (2, 42). Despite slow progression to cirrho-
sis, HCV-related mortality because of liver failure and
HCC has increased substantially since 1995, especially in
persons 45 years and older, with the greatest increases
seen in males and non-Hispanic blacks (43). HCV is an
important cause of premature mortality (43). In addi-
tion, chronic HCV affects well-being in all patients,
regardless of fibrosis (44), although the burden is great-
est in those with cirrhosis. In a recent cohort analysis of
528 cirrhotic HCV patients, baseline health-related
quality of life was significantly impaired, with the most
profound impairments seen in physical activity, energy,
vitality and fatigue (45). Eradication of HCV improves
health-related quality of life and work productivity (46).
The main goal of HCV treatment is to eradicate
HCV, thereby preventing progressive liver disease. SVR
is associated with reduced risk of HCC, histological
reversal of liver fibrosis and reduced risk of liver-related
death (4). Cure of HCV infection has also been associ-
ated with a decrease in all-cause mortality, decreased
incidence of diabetes and improved insulin resistance
(4, 47). A decrease in all-cause mortality was confirmed
in a study of 21 000 US Veterans (48). Survival advan-
tage was seen even in those without evidence of cirrho-
sis, suggesting an effect on non-liver related
comorbidities (cardiovascular disease, diabetes, non-
liver related cancers). These results were also supported
by a meta-analysis of more than 34 000 patients treated
with IFN-based therapy (Fig. 2) (49). This favours the
treatment of all patients infected with HCV, regardless
of degree of liver fibrosis. Another group prioritized for
treatment includes individuals at high risk for transmis-
sion, such as healthcare workers, haemodialysis patients,
incarcerated individuals, those of childbearing age, and
those who engage in high-risk behaviours (2).
Data from Phase 3 all-oral regimens suggest that cir-
rhosis remains a pretreatment factor that negatively
affects SVR. Longer durations of therapy are required to
maximize response in some cirrhotic patients, irrespec-
tive of genotype (8, 11, 27, 50). Thus, restricting care to
the cirrhotic population will impose higher costs per
treatment regimen. A recent cost-effectiveness model
examined the treatment of all patients infected with
HCV vs using a fibrosis-restricted decision model (e.g.
only treating F3–F4). The ‘treat all’ strategy was the
most cost-effective [incremental cost-effectiveness ratio
(ICER) of $15 709/quality-adjusted life year (QALY)]
and was also associated with the lowest risk of develop-
ing advanced liver disease (51).
Discussion
The HCV Council faculty felt strongly that this state-
ment should be rejected based on the proven benefit in
morbidity and mortality for eradicating HCV in patients
who are non-cirrhotic; along with the overall cost-effec-
tiveness advantage. Although prioritization of treatment
will likely continue to focus on those with advanced
disease, the group thought that there is strong evidence
to encourage therapy in all patients infected with HCV.
Statement 7: given the high-efficacy and low-viral
breakthrough rates, on-treatment viral load
monitoring is no longer required
Rationale and definition of statement
Direct-acting antiviral agent studies have reported viral
clearance rates of nearly 100% on therapy, eliminating
Fig. 2. Effects of sustained virological response (SVR) on risk of death. Meta-analysis of 129 studies; RR substantially reduced for all groups
with SVR. Adapted from Saleem et al. (49).
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the prognostic significance of early viral response and
response-guided therapy. The meaning of low-level pos-
itive viral load on therapy, though uncommon, is
unknown. Given the lack of prognostic significance, the
absence of futility rules and the inability to shorten
duration in rapid responders, the role of viral load mon-
itoring while on therapy is unclear. This statement
investigates the rationale for monitoring HCV viral load
while on therapy.
Summary of evidence
Several large multicenter trials show rapid achievement
of viral negativity in virtually all subjects, low rates of
viral breakthrough (<2%), lack of stopping rules for
futility, lack of prognostic significance based on the rate
of achieving viral clearance, or rules for response-guided
therapy (36, 52). SVR rates are over 90% with current
first-line therapy and virtually all fail through relapse.
As not even the rate of viral clearance predicts relapse,
the prognostic or clinical significance of measuring viral
load on-treatment is unclear.
Ledipasvir/SOF registration trials (ION-1, 2 and 3)
enrolled 1950 patients. Only two patients had viral
breakthrough (<1%). SVR rates were over 95% in all
groups, with 36 (1.8%) failures from relapse (7, 8, 15).
These findings are not unique to SOF-based therapy.
SAPPHIRE-I, II and TURQUOISE II evaluated 3D in
cirrhotic and non-cirrhotic genotype 1 patients (11, 50,
53). In more than 1100 patients, 1.5% experienced
breakthrough, and 2.2% relapsed. This is not likely to
change in the future as other investigational therapies
report similar results (54).
The lack of prognostic significance of a positive or
negative viral load at week 4 questions the utility of
monitoring on-treatment viral response. Several poten-
tial reasons for assessing on-treatment viral load remain.
Firstly, it is believed that a negative HCV RNA is a pow-
erful motivator that reinforces patient adherence. Sec-
ondly, a detectable HCV RNA may be a marker for non-
compliance or a drug–drug interaction (DDI) and, thus,
drug failure. Assessment can easily be incorporated at a
time when other labs are drawn. However, one would
have to be certain to exclude false-positive results and
prevent treatment disruption, as discontinuing treat-
ment could disadvantage many patients who could still
achieve SVR (36, 52).
Discussion
Achieving clearance of HCV RNA by week 4 with
highly potent DAA agents is expected in over 95% of
patients. The rate of viral breakthrough is <2%, and
virtually all failures to achieve SVR will be due to
non-compliance or relapse. There are no on-treat-
ment viral predictors of who will relapse, and it is
not possible to use on-treatment viral load monitor-
ing to develop either response-guided algorithms or
futility rules. Thus, the prognostic significance of
HCV-RNA on treatment is low.
Nevertheless, the panel felt that it was highly likely
that HCV RNA would be measured during treatment
in most patients, more as reinforcement of adherence
than as a true need to alter the therapeutic regimen.
They cautioned against discontinuing treatment in
patients with detectable viraemia unless non-adher-
ence could be established. They were strongly against
incorporating viral load measurements into algo-
rithms for continuing authorization of treatment by
payers, a requirement that has the potential to lead
to treatment interruption.
Statement 8: patients with decompensated
cirrhosis should be treated with an all-oral regimen
for HCV to improve survival
Rationale and definition of statement
The term decompensated cirrhosis implies that the
patient has experienced variceal haemorrhage, ascites,
spontaneous bacterial peritonitis, encephalopathy or
coagulopathy. IFN treatment is compromised by poor
tolerability, adverse events and low rates of virological
response (55). IFN-free regimens are the only options
available for patients with decompensated cirrhosis.
Until data support the use of PIs (NS3/4) in decompen-
sated cirrhosis (Child B/C), this class should also be
avoided.
Summary of evidence
Preliminary reports indicate that high rates of SVR
can be achieved in patients with decompensated cir-
rhosis. LDV/SOF/RBV was administered to approxi-
mately 100 patients with Child–Turcotte–Pugh
(CTP)-B or CTP-C cirrhosis for 12 or 24 weeks
(56). SVR rates were 87 and 89% overall, respec-
tively, and did not vary by CTP class (Fig. 3). The
regimen was well tolerated with few patients discon-
tinuing due to adverse events. Importantly, model
for end-stage liver disease (MELD) score decreased
in most patients, and serum albumin increased, indi-
cating that improvement in clinical status was also
associated with SVR. This same regimen was used to
treat patients with post-transplant recurrent hepatitis
C and also demonstrated high rates of SVR (96% in
CTP-A and 83–85% among CTP-B patients) that
was well tolerated. Similar improvement in MELD
and albumin were noted. The combination of DCV,
SOF and RBV for 12 weeks also demonstrated high
efficacy in 60 decompensated cirrhotics in the ALLY-
1 trial (57). Reported SVR12 rates were 92% in
Childs A, 94% in Childs B and 56% in Childs C.
Benefit from therapy in this fragile population may
require more than simply an improvement in biochemi-
cal parameters. The English EAP (Early Access Program)
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showed similar results in 467 patients with decompen-
sated cirrhosis treated with 12 weeks of all-oral therapy
(SOF/LDV/RBV, SOF/LDV, SOF/DCV/RBV or SOF/
DCV) (38). Overall SVR 12 rates were between 71 and
80%. Hepatic function (reflected by MELD score)
improved in 40%; however, the investigators felt that
the benefit was primarily gained in subjects younger
than 65 with a baseline albumin above 3.5 g/dl.
Several additional challenges exist in managing
decompensated cirrhosis, even with all-oral regimens.
Many patients with decompensated disease have
impaired renal function. SOF and RBV are cleared by
the kidney, and there are no dose recommendations for
patients with estimated glomerular filtration rate
(eGFR) <30 ml/min/1.73 m2 or in patients on dialysis
(58, 59). The clearance of other DAA agents may be
impaired by altered hepatic metabolism or portal-sys-
temic shunting; for example, simeprevir is not recom-
mended in CTP C cirrhosis due to substantially higher
simeprevir exposures (60). DDIs may alter therapeutic
efficacy and increase toxicity (61).
Discussion
The panel concurred that all-oral regimens were the
treatment of choice for patients with decompensated
liver disease, although PIs should be avoided in CTP C
cirrhosis. Clearly, SVR can be safely achieved in the
majority of patients. However, the major unanswered
question is whether SVR in a decompensated patient
will obviate the need for liver transplantation with con-
tinued improvement in hepatic function or whether it
will just provide a temporary respite from progressive
liver disease without affecting overall survival. It is
expected that long-term follow-up of these patients will
help answer this important question and inform
whether a pre-transplant or post-transplant antiviral
treatment strategy is most effective.
Statement 9: patients co-infected with HIV/HCV
should no longer be considered a ‘special
population’
Rationale and definition of statement
In the USA, up to 25% of those infected with the human
immunodeficiency virus (HIV) harbour co-infection
with HCV (62). The burden is thought to range from
250 000 to 300 000 patients with dual infection. Viewed
from the opposite direction, approximately 10% of
those with chronic HCV infection are also infected with
HIV. From a global perspective, these numbers are
much larger, with estimates of 4–8 million patients co-
infected with HIV/HCV. Historically, unique features of
HIV/HCV co-infection led to the designation of this
group as a ‘special population’.
Summary of evidence
To determine the validity of the proposed statement,
the definition of what constitutes a ‘special popula-
tion’ and the effect of such a designation requires
further scrutiny. Both the FDA and European Medici-
nes Agency (EMA) (USA and European drug regula-
tory bodies) regard HIV/HCV as a ‘special
population’ group. The designation is designed to
ensure that an appropriate number of subjects are
entered and treated in clinical trials leading to drug
approval so that both patients and healthcare provi-
ders have sufficient data on efficacy, safety and
unique management considerations. In the FDA
Guidance for Industry published in October 2013, the
agency specifically notes the need for appropriate
DDI studies with commonly used HIV medications
and safety data regarding loss of HIV efficacy. They
suggest that 300 co-infected patients are needed to
complete these assessments.
Fig. 3. Ledipasvir/sofosbuvir + ribavirin (RBV) in patients with decompensated cirrhosis: preliminary result of a prospective, multicenter
study. Randomized to sofosbuvir (SOF) + ledipasvir (LDV) (600 mg w/escalation) for 12 or 24 weeks. Patients with G1 or G4 and decompen-
sated cirrhosis. Most patients with MELD > 10 (MELD = 16–20 in 10–46%). Median albumin = 2.6–3.0 g/l; Median platelets = 71–88 K.
Flamm et al. (56).
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Several unique and relevant biological issues can affect
outcomes in HIV/HCV co-infected patients. These include
(i) faster rates of fibrotic progression (63, 64); (ii) increased
risk for hepatic decompensation (65, 66); c) higher viral
loads (67) and (iii) risk of DDIs, particularly between HCV
DAA agents and antiretroviral agents (61, 68).
Phase 2 and Phase 3 trial data oppose the need for a
‘special population’ designation in HIV/HCV co-infected
populations, as treatment response rates in coinfected
patients are similar to mono-infected subjects with HCV.
In the PHOTON-1 trial, treatment-na€ıve patients with
HCV/HIV co-infection were treated with SOF/RBV for
24 weeks if genotype 1 and 12 weeks if genotype 2 or 3.
Among those with HCV genotype 1, the SVR12 was 75%.
It was 88% in genotype 2 and 67% in genotype 3 (69).
SVR12 data among co-infected patients treated with
LDV/SOF for 12 weeks yielded 96% response rates among
a cohort of 335 patients, with 95% seen in na€ıve, 97% in
experienced, 96% without cirrhosis and 94% with cirrho-
sis (70). Other regimens continue to show efficacy compa-
rable to mono-infected subjects. Overall SVR12 rates of
97% were achieved with 12 weeks of DCV/SOF in HIV/
HCV co-infected subjects in ALLY-2. SVR rates were
highly independent of race, baseline HCV RNA, advanced
fibrosis, and prior treatment exposure (71). This study
also included an 8-week duration for treatment-na€ıve
subjects, 10% of whom had cirrhosis. However, relapse
rates were higher with an SVR12 of 76%. At this time,
shortened treatment duration (8 week) cannot be recom-
mended with this or any other regimen.
Of note, antiretroviral regimens were quite limited
in some trials. In other DAA studies, alternative dos-
ing regimens were required to adjust for DDIs. In the
simeprevir Phase 3 C212 trial, patients were not per-
mitted to use any HIV PIs or efavirenz (72). These
restrictions do not reflect real-world use of antiretro-
viral regimens. Future regimens, such as DCV/SOF,
will be compatible with a wide range of antiretrovi-
rals.
Discussion
The panel agreed that co-infected patients should
remain as a ‘special population’ based on the impor-
tance of DDI and monitoring the effects of treatment on
HIV disease. However, from an efficacy standpoint,
HIV/HCV co-infected patients do as well with potent
DAA regimens when treated for 12 weeks as do mono-
infected patients.
Statement 10: treatment of hepatitis C should
remain within the domain of hepatologists,
gastroenterologists and ID physicians
Rationale and definition of statement
HCV therapy is now characterized by short courses of
safe and well-tolerated, all-oral regimens with SVR rates
exceeding 90% (7, 8, 11, 15, 24, 50). However, the effect
of therapy will be blunted by ongoing deficits in the
diagnosis, linkage to care and treatment of chronic
HCV infection. Expansion of HCV treatment to non-
specialty providers such as primary care physicians
(PCPs) may help address the substantial burden of HCV
infection in the USA.
Summary of evidence
Sparse data exist to support or oppose the role of PCPs
in the management of HCV. Traditionally, HCV treat-
ment has remained within the realm of specialists. How-
ever, with the transition from highly complex regimens
to simplified regimens, an opportunity exists to expand
the treater pool to non-specialty providers.
The need to expand treatment capacity is under-
scored by profound deficits at each successive step
within the HCV care cascade: screening, diagnosis, link-
age to care, treatment initiation, treatment completion
and achievement of SVR (73–75). Among 99 166 veter-
ans with HCV, 60.0% underwent genotype confirma-
tion, 35.9% had no contraindications to HCV
treatment, 11.6% received standard HCV treatment
(PEG-IFN/RBV), 6.4% completed treatment and a
sobering 3.5% achieved SVR (76). A systematic review
and meta-analysis of 10 studies addressing the USA,
HCV care cascade revealed that only 50% of patients
were diagnosed and aware of their infection, 43% had
access to outpatient care, 27% had HCV RNA confirma-
tion, 16% were prescribed treatment and 9% achieved
SVR (77).
Although no controversy exists regarding the impor-
tant role of PCPs in the care cascade, questions remain
regarding the level of motivation, knowledge base and
capacity of PCPs in treating HCV. Literature suggests
significant deficits in both knowledge and current prac-
tices of PCPs and trainees regarding the diagnosis and
management of HCV. Despite the ability to identify risk
factors, few PCPs screen patients for risk factors, test for
HCV in patients with risk factors, provide hepatitis A
and B vaccinations, or refer infected patients to provi-
ders who have experience in antiviral therapy (78–85).
Only a small minority of PCPs is familiar with existing
therapies (85), and a recent survey revealed that 56% of
PCPs did not believe HCV can be cured (78). Further-
more, approximately three-quarters of surveyed PCPs
were unaware that the FDA had approved oral HCV
therapy, and approximately one-third expect to always
refer HCV patients to a specialist for management (79).
Many reports describe the ability to integrate antiviral
therapy within primary care. Unfortunately, most are
case reports and demonstration models within specific
clinical contexts, such as methadone clinics, community
health centers or prison clinics (86–88). The most
robust support comes from PROJECT ECHO, a
prospective observational cohort study in which out-
comes of 261 patients managed by PCPs at 21 rural
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satellite clinics were compared to 146 patients managed
by the primary university, which supervised HCV case
management via telemedicine for the satellite clinics.
The SVR outcomes between patients managed by spe-
cialty and PCPs were equivalent (89). Importantly, the
ECHO model relies upon formal, structured partnership
between the specialty providers with HCV expertise and
PCPs (90).
Literature suggests that adherence to general Medi-
care Physician Quality Reporting System (PQRS) HCV
quality measures (HCV RNA confirmation, HAV and
HBV vaccination) is higher for patients receiving care
by both a specialist and PCP than by either a specialist
or PCP alone, whereas adherence to treatment-related
quality measures (antivirals prescribed, HCV genotype
before treatment, HCV RNA at baseline and treatment
week 12) was higher for specialists with or without PCP
care than was seen in PCP care alone (91). Individuals
with optimum pretreatment care were more likely to
receive antiviral therapy (OR 3.2, 95% CI 2.9–3.5), com-
plete treatment (OR 1.26, 95% CI 1.13–1.43) and
achieve SVR (OR 1.3, 95% CI 1.01–1.65) (92). Patients
seen by a specialist are more likely to be prescribed
antiviral therapy (OR 9.34, 95% CI 8.03–10.87) (93),
although site experience (defined as ≥200 patients
treated with antiviral agents), not provider type, was
associated with treatment completion (OR 1.87, 95% CI
1.56–2.24) (94). In a large retrospect cohort study of US
veterans, only low site experience (defined as <25 trea-
ted patients) was associated with SVR (OR 0.71, 95% CI
0.56–0.90); no differences were observed by manage-
ment (gastroenterology or hepatology, infectious dis-
eases or internal medicine) (95). Simple and effective
regimens may amplify treatment experience and success
rates across all treater groups.
Discussion
The HCV Council panel recognizes that the evidence to
support or oppose this statement is poor. However,
based on expert consensus, the majority argues that
HCV treatment should remain within the realm of spe-
cialists who have the requisite knowledge, clinical judg-
ment and treatment experience required to provide the
best patient care. The current antiviral paradigm
remains complex, with the need for an expert clinician
to carefully consider multiple factors in guiding patients
in treatment decisions, such as HCV genotype and/or
subtype, stage of liver fibrosis, prior treatment experi-
ence, HIV co-infection and liver disease status (e.g.
decompensation, liver cancer, post-transplant). The
Council fully anticipates that as treatment transitions to
increasingly simple, short and effective regimens which
form the basis for ‘one size fits all’ across genotypes and
patient characteristics, the growing role of PCPs in HCV
treatment will be welcomed and considered an inevita-
ble and necessary step in our goal of HCV eradication in
the USA.
Conclusion
All-oral regimens have become the new standard of
care for chronic HCV and have already demonstrated
remarkable rates of SVR with well-tolerated, conve-
nient dosing across a broad population of patients
who previously could not tolerate nor benefit from
IFN-based regimens. Despite the rapid accumulation
of data and the prompt revisions of treatment recom-
mendations, numerous questions regarding optimal
management of certain populations and clinical scenar-
ios remain unanswered. The discussion above provides
a summary of evidenced-based expert opinion that
may help guide clinicians as additional information is
developed.
Acknowledgements
The authors thank the staff at Vindico Medical Educa-
tion for their assistance in the preparation of this manu-
script.
Financial support: This activity is supported by educa-
tional grants from AbbVie, Inc. and Gilead Sciences,
Inc.
Conflicts of interest: Nancy Reau, MD: Grant/Research
Support (paid directly to institution): Abbott Laborato-
ries, Boehringer Ingelheim, Bristol-Myers Squibb,
Genentech, Gilead, Janssen, Vertex; Consultant: Abbott
Laboratories, Gilead, Idenix. Michael W. Fried, MD:
Grant/Research Support (paid directly to institution):
Abbott Pharmaceuticals, Bristol-Myers Squibb, Genen-
tech, Gilead, Janssen, Merck, Vertex; Consultant: Abbott
Pharmaceuticals, Bristol-Myers Squibb, Gilead, Janssen,
Merck. David R. Nelson, MD: Grant/Research Support
(paid directly to institution): Abbott Pharmaceuticals,
Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithK-
line, Janssen, Merck. Robert S. Brown, Jr., MD: Grant/
Research Support (paid directly to institution): Abbott
Laboratories, Johnson & Johnson-Gilead, Merck-Vertex;
Consultant: Abbott Laboratories, Bristol-Myers Squibb,
Genentech, Johnson & Johnson-Gilead, Merck-Vertex.
Gregory T. Everson, MD: Grant/Research Support (paid
directly to institution): Abbott Pharmaceuticals, Bristol-
Myers Squibb, Genentech, GlaxoSmithKline, Janssen,
Merck; Speakers’ Bureau: Boehringer Ingelheim; Advi-
sory Board: Abbott Pharmaceuticals, Biotest, Boehringer
Ingelheim, Bristol-Myers Squibb, Eisai, Genentech,
Janssen, Novartis. Stuart C. Gordon, MD: Grant/
Research Support (paid directly to institution): Abbott
Pharmaceuticals, Bristol-Myers Squibb, Gilead, Merck;
Advisory Board: Abbott Pharmaceuticals, Amgen, Bris-
tol-Myers Squibb, Gilead, Merck; Expert Reviewer: Jans-
sen. Ira M. Jacobson, MD: Grant/Research Support
(paid directly to institution): Abbvie Pharmaceuticals,
Bristol-Myers Squibb, Gilead, Janssen, Merck; Consul-
tant: Abbvie Pharmaceuticals, Achillion, Bristol-Myers
Squibb, Enanta, Gilead, Janssen, Merck; Speakers’
Bureau: Bristol-Myers Squibb, Gilead, Janssen. Joseph
Liver International (2016)
© 2015 The Authors. Liver International Published by John Wiley & Sons Ltd498
HCV Council – critical appraisal of data Reau et al.
K. Lim, MD: Grant/Research Support (paid directly to
institution): Abbott Laboratories, Achillion, Boehringer
Ingelheim, Bristol-Myers Squibb, Gilead, Janssen, Ver-
tex; Consultant: Boehringer Ingelheim, Bristol-Myers
Squibb, Gilead, Janssen, Merck. Paul J. Pockros, MD:
Grant/Research Support (paid directly to institution):
Abbott Pharmaceuticals, Bristol-Myers Squibb, Gilead,
Janssen, Merck, Novartis, Roche; Consultant: Abbott
Pharmaceuticals, Bristol-Myers Squibb, Gilead, Janssen;
Speakers’ Bureau: Abbott Pharmaceuticals, Bristol-
Myers Squibb, Gilead, Janssen, Roche. K. Rajender
Reddy, MD: Grant/Research Support (paid directly to
institution): Abbott Pharmaceuticals, Bristol-Myers
Squibb, Gilead, Janssen, Merck–Vertex; Advisory Board:
Abbott Pharmaceuticals, Bristol-Myers Squibb, Genen-
tech–Gilead, Janssen, Merck, Vertex. Kenneth E. Sher-
man, MD, PhD: Grant/Research Support (paid directly
to institution): AbbVie, Bristol-Myers Squibb, Genen-
tech, Gilead, Merck, Vertex; Consultant: Medimmune;
Advisory Board: Merck; Data Monitoring Board: Jans-
sen, Synteract. Staff and Content Validation Reviewer
Disclosure: The staff involved with this activity and any
content validation reviewers of this activity have
reported no relevant financial relationships with com-
mercial interests. Signed disclosure(s) are on file at The
Duke University School of Medicine.
References
1. HARVONI (ledipasvir and sofosbuvir) tablets [package
insert]. Foster City, CA: Gilead Sciences; October, 2014.
Available at https://www.gilead.com/~/media/Files/pdfs/
medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed:
22 December 2014.
2. AASLD/IDSA/IAS–USA: Recommendations for testing,
managing, and treating hepatitis C. Available at http://
www.hcvguidelines.org. Accessed: 25 August 2015.
3. Nelson DR, Jensen DM, Sulkowski MS, et al. Hepatitis C
virus: a critical appraisal of new approaches to therapy.
Hepat Res Treat 2012; 2012: 138302.
4. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association
between sustained virological response and all-cause mor-
tality among patients with chronic hepatitis C and
advanced hepatic fibrosis. JAMA 2012; 308: 2584–93.
5. Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and
safety of peginterferon alfa-2a (40KD) plus ribavirin in
hepatitis C patients with advanced fibrosis and cirrhosis.
Hepatology 2009; 51: 388–97.
6. Vierling JM, Zeuzem S, Poordad F, et al. Safety and effi-
cacy of boceprevir/peginterferon/ribavirin for HCV G1
compensated cirrhotics: meta-analysis of 5 trials. J Hepatol
2014; 61: 200–9.
7. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbu-
vir for untreated HCV genotype 1 infection. N Engl J Med
2014; 370: 1889–98.
8. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and
sofosbuvir for previously treated HCV genotype 1 infec-
tion. N Engl J Med 2014; 370: 1483–93.
9. Bourliere M, Sulkowski MS, Omata M, et al. An inte-
grated safety and efficacy analysis of >500 patients with
compensated cirrhosis treated with ledipasvir/sofosbuvir
with or without ribavirin. Presented at: 65th Annual Meet-
ing of the American Association for the Study of Liver
Diseases (AASLD 2014); 7–11 November 2014; Boston,
MA. Abstract 82.
10. Bourliere M, Sulkowski MS, Omata M, et al. Ledi-
pasvir/sofosbuvir fixed dose combination is safe and effi-
cacious in cirrhotic patients who have previously failed
protease inhibitor-based triple therapy. Presented at: 65th
Annual Meeting of the American Association for the Study
of Liver Diseases (AASLD 2014); 7–11 November 2014;
Boston, MA. Abstract LB-6.
11. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitas-
vir and dasabuvir with ribavirin for hepatitis C with cir-
rhosis. N Engl J Med 2014; 370: 1973–82.
12. Jensen DM, Morgan TR, Marcellin P, et al. Early identifi-
cation of HCV genotype 1 patients responding to
24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
Hepatology 2006; 43: 954–60.
13. Pearlman BL, Ehleben C. Hepatitis C genotype 1 virus
with low viral load and rapid virologic response to pegin-
terferon/ribavirin obviates a protease inhibitor. Hepatology
2014; 59: 71–7.
14. Poordad F, Bronowicki JP, Gordon SC, et al. Factors that
predict response of patients with hepatitis C virus infec-
tion to boceprevir. Gastroenterology 2012; 143: 608–18.
15. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and
sofosbuvir for 8 or 12 weeks for chronic HCV without cir-
rhosis. N Engl J Med 2014; 370: 1879–88.
16. O’Brien TR, Lang Kuhs KA, Pfeiffer RM. Subgroup differ-
ences in response to 8 weeks of ledipasvir/sofosbuvir for
chronic hepatitis C. Open Forum Infect Dis 2014; 1: ofu110.
17. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of
interferon-free therapy for hepatitis C virus genotype 1. N
Engl J Med 2014; 370: 222–32.
18. Legrand-Abravanel F, Colson P, Leguillou-Guillemette H,
et al. Influence of the HCV subtype on the virological
response to pegylated interferon and ribavirin therapy.
J Med Virol 2009; 81: 2029–35.
19. Jacobson IM, McHutchison JG, Dusheiko G, et al.
Telaprevir for previously untreated chronic hepatitis C
virus infection. N Engl J Med 2011; 364: 2405–16.
20. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for
untreated chronic HCV genotype 1 infection. N Engl
J Med 2011; 364: 1195–206.
21. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with
pegylated interferon alfa 2a plus ribavirin in treatment-
naive patients with chronic hepatitis C virus genotype 1
infection (QUEST-1): a phase 3, randomised, double-
blind, placebo-controlled trial. Lancet 2014; 384: 403–13.
22. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previ-
ously untreated chronic hepatitis C infection. N Engl
J Med 2013; 368: 1878–87.
23. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with
pegylated interferon alfa-2a and ribavirin for treatment-
naive patients with hepatitis C genotype-1 infection
(ATOMIC): an open-label, randomised, multicentre phase
2 trial. Lancet 2013; 381: 2100–7.
24. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombi-
tasvir and dasabuvir with or without ribavirin for HCV. N
Engl J Med 2014; 370: 1983–92.
25. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbas-
vir combination therapy for treatment-naive cirrhotic and
Liver International (2016)
© 2015 The Authors. Liver International Published by John Wiley & Sons Ltd 499
Reau et al. HCV Council – critical appraisal of data
noncirrhotic patients with chronic hepatitis C virus Geno-
type 1, 4, or 6 infection: a randomized trial. Ann Intern
Med 2015; 163: 1–13.
26. Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir in
combination with PegIFN and ribavirin for 12 weeks pro-
vides high SVR rates in HCV-infected genotype 2 or 3
treatment experienced patients with and without compen-
sated cirrhosis: results from the LONESTAR-2 study. Pre-
sented at: 64th Annual Meeting of the American
Association for the Study of Liver Diseases (AASLD 2013);
1–5 November 2013; Washington, DC. Abstract LB-4.
27. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir
for hepatitis C genotype 2 or 3 in patients without treat-
ment options. N Engl J Med 2013; 368: 1867–77.
28. Foster GR, Strasser S, Christensen C, et al. Sofosbuvir-
based regimens are associated with high SVR rates
across genotypes and among patients with multiple
negative predictive factors. Presented at: 49th Annual
Meeting of the European Association for the Study of
the Liver (EASL 2014); 9–13 April 2014; London, Eng-
land. Abstract O66.
29. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al.
Daclatasvir plus sofosbuvir for previously treated or
untreated chronic HCV infection. N Engl J Med 2014; 370:
211–21.
30. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus
Sofosbuvir for HCV in Patients Coinfected with HIV-1. N
Engl J Med 2015; 373: 714–25.
31. Foster G. Sofosbuvir + peginterferon/ribavirin for
12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in
genotype 3 HCV infected patients and treatment-experi-
enced cirrhotic patients with genotype 2 HCV: the
BOSON study. Presented at: The International Liver Con-
gress (EASL 2015); 22-26 April 2015; Vienna, Austria.
Abstract L05.
32. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir
and ribavirin in HCV genotypes 2 and 3. N Engl J Med
2014; 370: 1993–2001.
33. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in
combination with peginterferon alfa-2a and ribavirin for
non-cirrhotic, treatment-naive patients with genotypes 1,
2, and 3 hepatitis C infection: a randomised, double-blind,
phase 2 trial. Lancet Infect Dis 2013; 13: 401–8.
34. Esteban R, Nyberg L, Lalezari J, et al. Successful retreat-
ment with sofosbuvir-containing regimens for HCV geno-
type 2 or 3 infected patients who failed prior sofosbuvir
plus ribavirin therapy. Presented at: 49th Annual Meeting
of the European Association for the Study of the Liver
(EASL 2014); 9–13 April 2014; London, England. Oral
Presentation O8.
35. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week
treatment with daclatasvir plus sofosbuvir in patients with
hepatitis C virus genotype 3 infection: ALLY-3 phase III
study. Hepatology 2015; 61: 1127–35.
36. Welzel TM, Herrmann E, Marcellin P, et al. On treatment
HCV RNA as a predictor of virologic response in the ledi-
pasvir/sofosbuvir phase 3 program for HCV genotype 1
infection: analysis of the ION-1, ION-2, and ION-3 stud-
ies. Poster presented at: 65th Annual Meeting of the Amer-
ican Association for the Study of Liver Diseases (AASLD
2014); 7–11 November 2014; Boston, MA. Poster 1932.
37. Hezode C, Ledinghen VD, Fontaine H, et al. Daclatasvir
plus sofosbuvir with or without ribavirin in patients with
HCV genotype 3 infection: interim analysis of a French
multicenter compassionate use program. Presented at: The
International Liver Congress (EASL 2015); 22–26 April
2015; Vienna, Austria. Abstract LP05.
38. Foster G. Treatment of decompensated HCV cirrhosis in
patients with diverse genotypes: 12 weeks sofosbuvir and
NS5A inhibitors with/without ribavirin is effective in HCV
genotypes 1 and 3. Presented at: The International Liver
Congress (EASL 2015); 22–26 April 2015; Vienna, Austria.
Abstract O002.
39. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV
genotype 3 is associated with an increased risk of cirrhosis
and hepatocellular cancer in a national sample of U.S.
Veterans with HCV. Hepatology 2014; 60: 98–105.
40. Everson GT, Tran TT, Towner WJ, et al. Safety and
efficacy of treatment with the interferon-free, ribavirin-
free combination of sofosbuvir + GS-5816 for 12 weeks
in treatment naive patients with genotype 1–6 HCV
infection. Presented at: 49th Annual Meeting of the
European Association for the Study of the Liver (EASL
2014); 9–13 April 2014; London, England. Oral Presen-
tation O111.
41. Mintz Z. The cost of a cure: new drugs may eradicate hep-
atitis C but are they worth it? International Business Times.
11 April 2014. Available at http://www.ibtimes.com/cost-cure-
new-drugs-may-eradicate-hepatitis-c-are-they-worth-it-1570671.
Accessed: 22 December 2014.
42. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW.
Aging of hepatitis C virus (HCV)-infected persons in the
United States: a multiple cohort model of HCV prevalence
and disease progression. Gastroenterology 2010; 138: 513–
21.
43. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing
trends in hepatitis C-related mortality in the United States,
1995-2004. Hepatology 2008; 47: 1128–35.
44. Younossi ZM, Stepanova M, Mishra A, et al. The impact of
chronic hepatitis C on resource utilisation and
in-patient mortality for Medicare beneficiaries between
2005 and 2010. Aliment Pharmacol Ther 2013; 38: 1065–75.
45. Younossi ZM, Stepanova M, Nader F, et al. Patient-
reported outcomes in chronic hepatitis C patients with cir-
rhosis treated with sofosbuvir-containing regimens. Hepa-
tology 2014; 59: 2161–9.
46. Younossi ZM, Stepanova M, Afdhal N, et al. Improvement
of health-related quality of life and work productivity in
chronic hepatitis C patients with early and advanced fibro-
sis treated with ledipasvir and sofosbuvir. J Hepatol 2015;
63: 337–45.
47. Pearlman BL, Traub N. Sustained virologic response to
antiviral therapy for chronic hepatitis C virus infection: a
cure and so much more. Clin Infect Dis 2011; 52: 889–900.
48. Backus LI, Boothroyd DB, Phillips BR, et al. A sustained
virologic response reduces risk of all-cause mortality in
patients with hepatitis C. Clin Gastroenterol Hepatol 2011;
9: 509–16.
49. Hill AM, Saleem J, Heath KA, Simmons B. Effects of sus-
tained virological response (SVR) on the risk of liver
transplant, hepatocellular carcinoma, death and re-infec-
tion: meta-analysis of 129 studies in 23,309 patients with
hepatitis C infection. Presented at: 65th Annual Meeting
of the American Association for the Study of Liver Dis-
eases (AASLD 2014); 7–11 November 2014; Boston, MA.
Abstract 44.
Liver International (2016)
© 2015 The Authors. Liver International Published by John Wiley & Sons Ltd500
HCV Council – critical appraisal of data Reau et al.
50. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV
with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
N Engl J Med 2014; 370: 1594–603.
51. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S.
Impact of interferon free regimens on clinical and cost
outcomes for chronic hepatitis C genotype 1 patients.
J Hepatol 2014; 60: 530–7.
52. Sulkowski MS, Fried MW, Ozaras R, et al. Time to
viral suppression is not related to achievement of
SVR12 in HCV GT1-infected patients treated with
ABT-450/4/ombitasvir and dasabuvir with or without
ribavirin. Poster presented at: 65th Annual Meeting of
the American Association for the Study of Liver Dis-
eases (AASLD 2014); 7–11 November 2014; Boston,
MA. Poster 1950.
53. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of
HCV with ABT-450/r-ombitasvir and dasabuvir with rib-
avirin. N Engl J Med 2014; 370: 1604–14.
54. Lawitz E, Vierling JM, Murillo A, et al. High efficacy and
safety of the all-oral combination regimen, MK-5172/MK-
8742 + /- RBV for 12 weeks in HCV genotype 1 infected
patients: the C-WORTHY study. Presented at: 64th
Annual Meeting of the American Association for the Study
of Liver Diseases (AASLD 2013); 1–5 November 2013;
Washington, DC. Abstract 76.
55. Everson GT, Terrault NA, Lok AS, et al. A randomized
controlled trial of pretransplant antiviral therapy to pre-
vent recurrence of hepatitis C after liver transplantation.
Hepatology 2013; 57: 1752–62.
56. Flamm SL, Everson GT, Charlton M, et al. Ledipasvir/so-
fosbuvir with ribavirin for the treatment of HCV in
patients with decompensated cirrhosis: preliminary results
of a prospective multicenter study. Presented at: 65th
Annual Meeting of the American Association for the Study
of Liver Diseases (AASLD 2014); 7–11 November 2014;
Boston, MA. Abstract 239.
57. Poordad F. Daclatasvir, sofosbuvir, and ribavirin combi-
nation for HCV patients with advanced cirrhosis or post-
transplant recurrence: phase 3 ALLY-1 study. Presented at:
EASL 50th The International Liver Congress 2015; 22–26
April 2015; Vienna, Austria. Abstract LO8.
58. COPEGUS (ribavirin) tablets [package insert]. South San
Francisco, CA: Genentech USA; August 2011. Available at
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/
021511s020lbl.pdf. Accessed: 22 December 2014.
59. SOVALDI (sofosbuvir) tablets [package insert]. Foster
City, CA: Gilead Sciences; December 2013. Available at
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/
204671s000lbl.pdf. Accessed: 22 December 2014.
60. OLYSIO (simeprevir) capsules [package insert]. Titusville,
NJ: Janssen Therapeutics; 2013. Available at http://www.
accessdata.fda.gov/drugsatfda_docs/label/2013/204671s000
lbl.pdf. Accessed: 24 February 2015.
61. Kiser JJ, Burton JR Jr, Everson GT. Drug–drug interactions
during antiviral therapy for chronic hepatitis C. Nat Rev
Gastroenterol Hepatol 2013; 10: 596–606.
62. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis
C virus prevalence among patients infected with human
immunodeficiency virus: a cross-sectional analysis of the
US adult AIDS Clinical Trials Group. Clin Infect Dis 2002;
34: 831–7.
63. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis
progression in human immunodeficiency virus and hep-
atitis C virus coinfected patients. The Multivirc Group.
Hepatology 1999; 30: 1054–8.
64. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibro-
sis progression in HIV/HCV-coinfected patients with suc-
cessful HIV suppression using antiretroviral therapy. J
Hepatol 2006; 44: 47–55.
65. Lo Re V III, Kallan MJ, Tate JP, et al. Hepatic decompen-
sation in antiretroviral-treated patients co-infected with
HIV and hepatitis C virus compared with hepatitis C
virus-monoinfected patients: a cohort study. Ann Intern
Med 2014; 160: 369–79.
66. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of
antiretroviral therapy on liver-related mortality in patients
with HIV and hepatitis C virus coinfection. Lancet 2003;
362: 1708–13.
67. Sherman KE, Shire NJ, Rouster SD, et al. Viral kinetics in
hepatitis C or hepatitis C/human immunodeficiency virus-
infected patients. Gastroenterology 2005; 128: 313–27.
68. Kiser JJ, Flexner C. Direct-acting antiviral agents for hep-
atitis C virus infection. Annu Rev Pharmacol Toxicol 2013;
53: 427–49.
69. Naggie S, Sulkowski M, Lalezari J, et al. Sofosbuvir plus
ribavirin for HCV genotype 1–3 infection in HIV coin-
fected patients (PHOTON-1). Presented at: 21st Confer-
ence on Retroviruses and Opportunistic Infections
(CROI); 3–6 March 2014; Boston, MA. Abstract 26.
70. Naggie S, Sulkowski M, Lalezari J, et al. Ledipasvir/sofos-
buvir for 12 weeks in patients coinfected with HCV and
HIV-1. Presented at: Conference on Retroviruses and
Opportunistic Infections (CROI 2015); 3–6 March 2014;
Seattle, WA. Abstract 152LB.
71. Wyles D, Ruane P, Sulkowski M, et al. Daclatasvir in com-
bination with sofosbuvir for HIV/HCV coinfection:
ALLY-2 study. Presented at: Conference on Retroviruses
and Opportunistic Infections (CROI 2015); 23–26 Febru-
ary 2015; Seattle, WA. Abstract 151LB.
72. Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir
(TMC435) with pegylated interferon/ribavirin in patients
coinfected with HCV genotype 1 and HIV-1: a phase 3
study. Clin Infect Dis 2014; 59: 1579–87.
73. Afdhal NH, Zeuzem S, Schooley RT, et al. The new para-
digm of hepatitis C therapy: integration of oral therapies
into best practices. J Viral Hepat 2013; 20: 745–60.
74. Denniston MM, Klevens RM, McQuillan GM, Jiles RB.
Awareness of infection, knowledge of hepatitis C, and
medical follow-up among individuals testing positive for
hepatitis C: National Health and Nutrition Examination
Survey 2001–2008. Hepatology 2012; 55: 1652–61.
75. Holmberg SD, Spradling PR, Moorman AC, Denniston
MM. Hepatitis C in the United States. N Engl J Med 2013;
368: 1859–61.
76. Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB.
Gaps in the achievement of effectiveness of HCV treat-
ment in national VA practice. J Hepatol 2012; 56: 320–5.
77. Yehia BR, Schranz AJ, Umscheid CA. Lo Re V, 3rd. The
treatment cascade for chronic hepatitis C virus infection
in the United States: a systematic review and meta-analy-
sis. PLoS One 2014; 9: e101554.
78. Evaluating the challenges and impact of birth cohort
screening for hepatitis C in the primary care clinic: a
report of current evidence, practice patterns, and opportu-
nities for improvements in care [news release]. Baltimore,
MD: Duke University School of Medicine, Med-IQ; 21
Liver International (2016)
© 2015 The Authors. Liver International Published by John Wiley & Sons Ltd 501
Reau et al. HCV Council – critical appraisal of data
November 2013. Available at http://www.med-iq.com/
files/PR/2013/pr11-21-13.html. Accessed: 10 July 2014.
79. Primary care physicians in an interferon-free world:
how will the availability of safer and more effective
oral therapies impact the role of PCPs in treating
HCV patients? [news release]. Burlington, MA: Decision
Resources; 19 June 2014. Available at http://www.deci-
sionresources.com/News-and-Events/Press-Releases/Direct-
Acting-Antivirals-for-Hepatitis-C-61914. Accessed: 10
July 2014.
80. Coppola AG, Karakousis PC, Metz DC, et al. Hepatitis C
knowledge among primary care residents: is our teaching
adequate for the times? Am J Gastroenterol 2004; 99: 1720–5.
81. Ferrante JM, Winston DG, Chen PH, de la Torre AN.
Family physicians’ knowledge and screening of chronic
hepatitis and liver cancer. Fam Med 2008; 40: 345–51.
82. Nicklin DE, Schultz C, Brensinger CM, Wilson JP. Current
care of hepatitis C-positive patients by primary care physi-
cians in an integrated delivery system. J Am Board Fam
Pract 1999; 12: 427–35.
83. Shehab TM, Orrego M, Chunduri R, Lok AS. Identifica-
tion and management of hepatitis C patients in primary
care clinics. Am J Gastroenterol 2003; 98: 639–44.
84. Shehab TM, Sonnad SS, Jeffries M, Gunaratnum N, Lok
AS. Current practice patterns of primary care physicians
in the management of patients with hepatitis C. Hepatol-
ogy 1999; 30: 794–800.
85. Shehab TM, Sonnad SS, Lok AS. Management of hepatitis
C patients by primary care physicians in the USA: results
of a national survey. J Viral Hepat 2001; 8: 377–83.
86. Bruce RD, Eiserman J, Acosta A, et al. Developing a modi-
fied directly observed therapy intervention for hepatitis C
treatment in a methadone maintenance program: implica-
tions for program replication. Am J Drug Alcohol Abuse
2012; 38: 206–12.
87. Jack K, Willott S, Manners J, Varnam MA, Thomson
BJ. Clinical trial: a primary-care-based model for the
delivery of anti-viral treatment to injecting drug users
infected with hepatitis C. Aliment Pharmacol Ther
2009; 29: 38–45.
88. Litwin AH, Harris KA Jr, Nahvi S, et al. Successful
treatment of chronic hepatitis C with pegylated inter-
feron in combination with ribavirin in a methadone
maintenance treatment program. J Subst Abuse Treat
2009; 37: 32–40.
89. Arora S, Thornton K, Murata G, et al. Outcomes of treat-
ment for hepatitis C virus infection by primary care provi-
ders. N Engl J Med 2011; 364: 2199–207.
90. Mitruka K, Thornton K, Cusick S, et al. Expanding pri-
mary care capacity to treat hepatitis C virus infection
through an evidence-based care model–Arizona and Utah,
2012–2014. MMWR Morb Mortal Wkly Rep 2014; 63:
393–8.
91. Kanwal F, Schnitzler MS, Bacon BR, et al. Quality of care
in patients with chronic hepatitis C virus infection: a
cohort study. Ann Intern Med 2010; 153: 231–9.
92. Kanwal F, Hoang T, Chrusciel T, et al. Process of care for
hepatitis C infection is linked to treatment outcome and
virologic response. Clin Gastroenterol Hepatol 2012; 10:
1270–7.
93. Kramer JR, Kanwal F, Richardson P, et al. Importance of
patient, provider, and facility predictors of hepatitis C
virus treatment in veterans: a national study. Am J Gas-
troenterol 2011; 106: 483–91.
94. Butt AA, McGinnis KA, Skanderson M, Justice AC.
Hepatitis C treatment completion rates in routine clinical
care. Liver Int 2010; 30: 240–50.
95. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predic-
tors of response of US veterans to treatment for the hep-
atitis C virus. Hepatology 2007; 46: 37–47.
Liver International (2016)
© 2015 The Authors. Liver International Published by John Wiley & Sons Ltd502
HCV Council – critical appraisal of data Reau et al.
